Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-4 of 4 for your search:
Drug:
lymphokine-activated killer cells
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of Haploidentical Allogeneic Aldesleukin-Activated Natural Killer Cells and Aldesleukin Following Chemoimmunotherapy Comprising Rituximab, Fludarabine, and Cyclophosphamide in Patients With CD20-Positive Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UMN-2007LS064
, UMN-2007LS064, MT2007-12, UMN-0707M13561, NCT00625729
2.
Phase II Study of Haploidentical Allogeneic Aldesleukin-Activated Natural Killer Cells and Aldesleukin Following a Preparative Regimen Comprising Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Patients With Recurrent and/or Metastatic Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UMN-2007LS138
, UMN-2007LS138, UMN-MT2007-19R, UMN-WCC-53, UMN-0712M23462, NCT00652899
3.
Phase II Randomized Study of Intralesional Lymphokine-Activated Killer Cells Versus Polifeprosan 20 With Carmustine Implant (GliadelĀ® Wafer) as Consolidation Therapy After Primary Therapy in Patients With Newly Diagnosed Resectable Glioblastoma Multiforme
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
HOAG-HCC-08-01
, HCC 08-01, NCT00814593
4.
Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UARK 2003-18
, NCT00089453
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute